Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Koenig, Lars M., Boehmer, Daniel F.R., Metzger, Philipp, Schnurr, Max, Endres, Stefan, Rothenfusser, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365736/
https://www.ncbi.nlm.nih.gov/pubmed/32678432
http://dx.doi.org/10.1084/jem.20201342
_version_ 1783560092304539648
author Koenig, Lars M.
Boehmer, Daniel F.R.
Metzger, Philipp
Schnurr, Max
Endres, Stefan
Rothenfusser, Simon
author_facet Koenig, Lars M.
Boehmer, Daniel F.R.
Metzger, Philipp
Schnurr, Max
Endres, Stefan
Rothenfusser, Simon
author_sort Koenig, Lars M.
collection PubMed
description An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
format Online
Article
Text
id pubmed-7365736
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-73657362020-08-07 Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19 Koenig, Lars M. Boehmer, Daniel F.R. Metzger, Philipp Schnurr, Max Endres, Stefan Rothenfusser, Simon J Exp Med Viewpoint An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation. Rockefeller University Press 2020-07-17 /pmc/articles/PMC7365736/ /pubmed/32678432 http://dx.doi.org/10.1084/jem.20201342 Text en © 2020 Koenig et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Viewpoint
Koenig, Lars M.
Boehmer, Daniel F.R.
Metzger, Philipp
Schnurr, Max
Endres, Stefan
Rothenfusser, Simon
Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
title Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
title_full Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
title_fullStr Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
title_full_unstemmed Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
title_short Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
title_sort blocking inflammation on the way: rationale for cxcr2 antagonists for the treatment of covid-19
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365736/
https://www.ncbi.nlm.nih.gov/pubmed/32678432
http://dx.doi.org/10.1084/jem.20201342
work_keys_str_mv AT koeniglarsm blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19
AT boehmerdanielfr blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19
AT metzgerphilipp blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19
AT schnurrmax blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19
AT endresstefan blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19
AT rothenfussersimon blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19